Key result
Paclitaxel and bevacizumab yielded a 4-month non-progression rate of 62.5% in patients with metastatic or unresectable angiosarcoma, with similar efficacy between Q3 week and weekly regimens.
Why the study?
Does paclitaxel combined with bevacizumab provide efficacy and safety in patients with metastatic or unresectable angiosarcoma?
Does paclitaxel combined with bevacizumab provide efficacy and safety in patients with metastatic or unresectable angiosarcoma?
Paclitaxel combined with bevacizumab is an active regimen for metastatic or unresectable angiosarcoma, with comparable efficacy and safety between every-3-week and weekly paclitaxel dosing.
Paclitaxel-bevacizumab shows activity in advanced angiosarcoma; leaves open optimal scheduling and need for randomized confirmation.
Paclitaxel (P) and bevacizumab (B) are agents that provide clinical benefit in advanced angiosarcoma (AS). The objective of this study was to assess the efficacy and safety of P-B in two different scheduled regimens. Patients were to receive P 200mg/m2 IV with B 15mg/kg IV every 21 days (Regimen A) or P 90mg/m2 IV weekly D1, 8, 15 with B 15mg/kg IV D1 of a 28 day cycle (Regimen B) x6 cycles. Maintenance B followed at a dose of 15 mg/kg intravenously once every 21 days. The primary end point was 4 month non-progression rate (NPR). A total of 16 patients were enrolled. 4 month NPR was 62.5% with median overall survival 16 months and median progression free survival 5.06 months. 11 patients made it to cycle 3 and were evaluable for response with 1 CR (9%), 4 PR (36%), 2 SD (18%), and 6 PD (36%). There were ten grade 3 toxicities and four grade 4 toxicities. The breakdown between the two regimens revealed comparable efficacy and safety. Paclitaxel and Bevacizumab is an active regimen in angiosarcoma. Q3 week and weekly paclitaxel appear similar in efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Bui et al. (2018) studied metastatic or unresectable angiosarcoma (n=16). Paclitaxel and bevacizumab (Q3 week or weekly) was evaluated on 4 month non-progression rate (NPR). Paclitaxel and bevacizumab yielded a 4-month non-progression rate of 62.5% in patients with metastatic or unresectable angiosarcoma, with similar efficacy between Q3 week and weekly regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: